ABLYNX ANNOUNCES BOARD CHANGES
07 Février 2018 - 7:00AM
GHENT, Belgium, 7
February 2018 - Ablynx NV [Euronext Brussels
and Nasdaq: ABLX] today announced that Dr Bo Jesper Hansen,
acting as permanent representative of Orfacare Consulting GmbH, has
decided to resign from the Board of Directors with immediate effect
for personal reasons. Having contributed to Ablynx's recent M&A
activities, and served on the Board since 2013, Dr Hansen will now
focus on other opportunities. He will be succeeded by Dr Russell G.
Greig, acting as a permanent representative of Greig Biotechnology
Global Consulting Inc., who has been a non-executive Director of
Ablynx since 2012, and has been unanimously elected by the Ablynx
Board as the new Chairman.
Dr Greig is an industry veteran
and is currently Chairman of AM Pharma and MedEye (The NL), Sanifit
(Spain and the USA), eTheRNA (Belgium), and a non-executive
Director of TiGenix (Belgium). Following a 28-year career at GSK
where he held the positions of President of both GSK
Pharmaceuticals International and SROne (the Venture Arm of GSK),
Dr Greig has served as Chairman of Novagali (sold to Santen),
Isconova (to Novavax), Syntaxin (to Ipsen), and as a Venture
Partner at Kurma Life Sciences (France).
Dr Edwin Moses,
Chief Executive Officer at Ablynx, commented:
"We are very fortunate to have a very suitable successor for Bo
Jesper, allowing for an orderly transition at this time. Russell
knows the company extremely well and will be an important asset
during the next months."
Dr Russell Greig,
commented:
"I am delighted to accept this position, having worked with the
Ablynx Board over the past five years. My goal will be to fully
support the proposed acquisition of the Company by Sanofi as
recommended by the Ablynx Board."
From 7 February
2018, the composition of the Board of Ablynx is as follows:
-
Russell Greig, Chairman of the Board, acting as
permanent representative of Greig Biotechnology Global Consulting
Inc.
-
Edwin Moses, Director and Chief Executive
Officer
-
William Jenkins, Independent Director, acting as
principal of William Jenkins Pharma Consulting
-
Catherine Moukheibir, Independent Director
-
Remi Vermeiren, Independent Director
-
Lutgart Van den Berghe, Independent Director,
acting as permanent representative of NV Feadon
-
Hilde Windels, Independent Director, acting as
permanent representative of Hilde Windels BVBA
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies®, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024